Okkes Kuybu

Okkes Kuybu practices at Community Health Partners in Clovis, California.

Okkes Kuybu's NPI, 1336502707, was assigned on April 1, 2016. Okkes Kuybu holds California license A185015.

Okkes Kuybu's primary practice is Community Health Partners, at 789 N Medical Center E Dr, Clovis, CA 93611 in Fresno County. The practice phone is (559) 324-4952.

Okkes Kuybu's primary practice is Community Health Partners in Clovis, California. Okkes Kuybu is also affiliated with Clovis Community Medical Center. The medical group on file is Community Health Partners. Dmand AI also links Okkes Kuybu to 4 more hospitals, 3 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Okkes Kuybu practices, 8 sites in all. Vendor and product names are available with a free account.

Neurology is Okkes Kuybu's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Okkes Kuybu is board certified in neurology by the American Board of Psychiatry and Neurology. Dmand AI has Okkes Kuybu's licenses on file in 4 states: California, Maryland, Pennsylvania and Louisiana.

Dmand AI lists cerebrovascular disease and stroke among the conditions Okkes Kuybu treats.

CMS data shows 521 Medicare services from Okkes Kuybu across 17 procedure codes in 2024, for 209 Medicare patients. Medicare paid $94,848 for them.

CMS counts 209 Medicare patients who saw Okkes Kuybu in 2024. The largest group is 75 to 84, with 84 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 53% are also on Medicaid. Their average risk score is 1.87, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Okkes Kuybu's median patient age at 67, with 56% women.

In 2024, Okkes Kuybu wrote 71 Medicare Part D claims for 23 patients. 89% of them were for generic drugs. CMS names the drug for 28 of them, across 2 drugs with 11 or more claims each, at $349 in total drug cost. In 2022, CMS named 14 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 92 out of 100 for Okkes Kuybu for performance year 2024, reported as part of a group. Okkes Kuybu accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 24 papers to Okkes Kuybu, published from 2019 to 2025. 2024 was the busiest year, with 6. The most frequent topics are Stroke, Stents and Brain Ischemia. Okkes Kuybu has published most often in J Neurointerv Surg. Okkes Kuybu's most frequent co-authors are Omar Tanweer, MD, Ricardo Alexandre Hanel, MD, PhD and Bradley Gross, MD.

CMS Open Payments shows 128 general payments to Okkes Kuybu from 14 drug and device companies from 2020 to 2025. Travel and lodging make up the largest share, 58% of the total. Medtronic, Inc. paid the most, $4,210.

Okkes Kuybu is in network with 18 carriers, including Aetna, Elevance and Highmark. Medicare plans come from the most carriers, 12. Check the plan with the practice before a visit.